{"id":"W1947519512","doi":"10.1007/s40273-015-0332-5","title":"Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Health Canada; Novartis Pharmaceuticals Canada; GlaxoSmithKline","keywords":"Chlorambucil; Ofatumumab; Medicine; Fludarabine; Quality-adjusted life year; Cost effectiveness; Life expectancy; Actuarial science; Internal medicine; Chronic lymphocytic leukemia; Population; Chemotherapy; Leukemia; Environmental health; Economics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009058444,0.0003834999,0.0009821975,0.0009217831,0.001240563,0.002061456,0.00145967,0.0008956497,0.003470455],"category_scores_gemma":[0.007266031,0.0002910308,0.001537699,0.002347984,0.0007281181,0.0005333808,0.0007744284,0.001437147,0.00009509454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.1176543,"about_ca_system_score_gemma":0.1108794,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9896103,"about_ca_topic_score_gemma":0.9936138,"domain_scores_codex":[0.9983433,0.000380837,0.0001032717,0.0001161248,0.0004031927,0.0006531224],"domain_scores_gemma":[0.9954252,0.0008259555,0.0006250296,0.00004515639,0.001186223,0.00189253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.05613885,0.002807928,0.5989739,0.004084168,0.005510935,0.001780306,0.001094247,0.05071483,0.001659488,0.009816272,0.04474003,0.222679],"study_design_scores_gemma":[0.01502081,0.004536469,0.8989024,0.001978743,0.007115874,0.0009840264,0.004473668,0.04217777,0.0009237475,0.001628524,0.02200975,0.0002483061],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9587759,0.01707459,0.0001654682,0.0105927,0.0002215579,0.000262917,0.004599758,0.00003231155,0.008275007],"genre_scores_gemma":[0.9930276,0.004139416,0.0002043717,0.000659827,0.00005112544,0.00003166469,0.0008342193,0.000006800019,0.001044856],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1176543,"threshold_uncertainty_score":0.853646,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07660397386840974,"score_gpt":0.3576827904738943,"score_spread":0.2810788166054846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}